Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Rees

Showing results (151-160 of 175) with videos related to

Pageof 18
Sort By:
The New England Journal of Medicine|December 9, 2015
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive EventsMatthew M Heeney, Carolyn C Hoppe, Miguel R Abboud, et al.
Journal of Medicinal Chemistry|July 29, 2015
Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAPGianni Chessari, Ildiko M Buck, James E H Day, et al.
Haematologica|May 28, 2017
Recommendations regarding splenectomy in hereditary hemolytic anemiasAchille Iolascon, Immacolata Andolfo, Wilma Barcellini, et al.
Pediatric Blood & Cancer|March 27, 2015
13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 studyMariane De Montalembert, Miguel R Abboud, Anne Fiquet, et al.
Trials|October 11, 2021
Study of montelukast in children with sickle cell disease (SMILES): a study protocol for a randomised controlled trialAnna M Hood, Hanne Stotesbury, Melanie Kölbel, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinaseChristopher N Johnson, Valerio Berdini, Lijs Beke, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper KinaseChristopher N Johnson, Christophe Adelinet, Valerio Berdini, et al.
Journal of Medicinal Chemistry|January 16, 2009
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activitySteven Howard, Valerio Berdini, John A Boulstridge, et al.
Journal of Medicinal Chemistry|July 29, 2010
Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug designAndrew J Woodhead, Hayley Angove, Maria G Carr, et al.
Nature Communications|March 20, 2021
Red blood cell mannoses as phagocytic ligands mediating both sickle cell anaemia and malaria resistanceHuan Cao, Aristotelis Antonopoulos, Sadie Henderson, et al.
Pageof 18

Showing results (151-160 of 175) with videos related to

Sort By:
Pageof 18
The New England Journal of Medicine|December 9, 2015
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive EventsMatthew M Heeney, Carolyn C Hoppe, Miguel R Abboud, et al.
Journal of Medicinal Chemistry|July 29, 2015
Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAPGianni Chessari, Ildiko M Buck, James E H Day, et al.
Haematologica|May 28, 2017
Recommendations regarding splenectomy in hereditary hemolytic anemiasAchille Iolascon, Immacolata Andolfo, Wilma Barcellini, et al.
Pediatric Blood & Cancer|March 27, 2015
13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 studyMariane De Montalembert, Miguel R Abboud, Anne Fiquet, et al.
Trials|October 11, 2021
Study of montelukast in children with sickle cell disease (SMILES): a study protocol for a randomised controlled trialAnna M Hood, Hanne Stotesbury, Melanie Kölbel, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinaseChristopher N Johnson, Valerio Berdini, Lijs Beke, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper KinaseChristopher N Johnson, Christophe Adelinet, Valerio Berdini, et al.
Journal of Medicinal Chemistry|January 16, 2009
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activitySteven Howard, Valerio Berdini, John A Boulstridge, et al.
Journal of Medicinal Chemistry|July 29, 2010
Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug designAndrew J Woodhead, Hayley Angove, Maria G Carr, et al.
Nature Communications|March 20, 2021
Red blood cell mannoses as phagocytic ligands mediating both sickle cell anaemia and malaria resistanceHuan Cao, Aristotelis Antonopoulos, Sadie Henderson, et al.
Pageof 18